Table 4. Multiple logistic regression analysis for predictors of anemia in HAART experienced HIV patients involved in the study, south west Ethiopia, 2012.

Variables		COR (95% CI)	P-value	AOR (95% CI)	p-value
HAART regimen	D4T/3TC/NVP	0.074 (0.008–0.714)	0.024	0.11 (0.01–1.24)	0.074
	ZDV/3TC/NVP	0.148 (0.025–0.89)	0.037	0.09 (0.012–0.68)	0.019
	TDF/3TC/NVP	0.67 (0.097–4.58)	0.68	0.98 (0.12–8.99)	0.987
	TDF/3TC/EFV	0.76 (0.198–2.93)	0.69	0.301 (0.058–1.57)	0.154
	D4T/3TC/EFV	0.286 (0.027–3.01)	0.297	0.37 (0.03–4.82)	0.446
	ZDV/3TC/EFV	1 (ref)		1 (ref)
Duration of HAART in months	3–20	1 (ref)		1 (ref)
	20–36	00.242 (0.067–0.881)	0.031	.023 (0.038–0.789)	.023
	36–60	0.043 (0.005–0.36)	0.004	.007 (0.003–0.404)	.007
	>60	0.327 (0.077–1.394)	0.131	.215 (0.053–1.932)	.215

NB: ZDV = Zidovudine, d4T = Stavudine, 3TC = Lamivudine, NVP = Neverapine, TDF = Tenofovir, EFV = Efavirenz.